Ana Fernández

Biomarkers characterization of circulating tumour cells in breast cancer patients

F. Solé, M. Salido, J. Albanell, 2012, Breast Cancer Research.

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study

E. Gallardo, M. Salgado, R. Pazo-Cid, 2018, BMC Cancer.

CD133 expression in circulating tumor cells from breast cancer patients: Potential role in resistance to chemotherapy

F. Solé, M. Salido, M. Delgado-Rodríguez, 2013, International journal of cancer.

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study

E. Gallardo, M. Salgado, R. Pazo-Cid, 2018, BMC Cancer.

Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study

R. López-López, M. Abal, L. Muinelo-Romay, 2017, International journal of molecular sciences.

The Impact of Peritoneal Metastases in Epithelial Ovarian Cancer With Positive Nodes

J. Magrina, P. Magtibay, T. Pérez-Medina, 2011, International Journal of Gynecologic Cancer.

Circulating tumour cells in peripheral blood: potential impact on breast cancer outcome

José A. Lorente, J. Lorente, P. Rovira, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2- early breast cancer (EBC) patients.

S. Ferree, N. Dowidar, C. Schaper, 2015 .